Results 61 to 70 of about 19,412 (203)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan

Current Oncology
Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear.
Jerry Shu-Hung Kuo, Cheng-Yu Chang, Shih-Chieh Chang, Yu-Feng Wei, Chung-Yu Chen   +4 more
doaj   +1 more source

LINC01605 Predicts the Poor Prognosis of Non‐Small Cell Lung Cancer and Promotes Chemotherapy Resistance by Regulating miR‐7111‐5p/ELK1

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Non‐small cell lung cancer (NSCLC) is characterized by high incidence, mortality, and poor patient prognosis, with chemotherapy resistance being a common challenge. This research intends to identify key molecules involved in NSCLC and elucidate the regulatory role of the LINC01605/miR‐7111‐5p/ELK1 axis in chemotherapy resistance. LINC01605 and
Fang Zhang, Zhi‐Liang Yang, Tian‐Tian Qin, Guo‐Jun Zhang, Xiang Li   +4 more
wiley   +1 more source

Video – INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

, 2022
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib.
Karl Maria Schumacher (11850371), Xiuning Le (11850350), Svenja Adrian (11850365), Viola W Zhu (11850359), Egbert F Smit (9252899), Masahire Morise (11850356), Julien Mazieres (1837), Yi-Long Wu (154004), Figshare Future Science Group (6457551), Daniel Tan (840024), How Soon Hin (11850353), Kristina H Holmberg (11850362), Niki Karachaliou (458283), Jo Raskin (8677218), Ernest Nadal (709876), Sabine Brutlach (11850368), Christophe Dooms (2938749), Barbara Ellers-Lenz (11294394), Lye Mun Tho (8505159)   +18 more
core   +1 more source

Osimertinib za zdravljenje nedrobnoceličnega pljučnega raka [PDF]

, 2019
Osimertinib je zdravilo za zdravljenje pljučnega raka, ki ima prisotno posebno spremembo gena za EGFR, t. i. mutacijo T790M. Osimertinib uvrščamo v skupino zdravil, ki jih imenujemo zaviralci protein-kinaze in so na voljo v obliki tablet.
Vidovič, Dušanka, Unk, Mojca
core   +1 more source

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease

JTO Clinical and Research Reports
Introduction: Interstitial lung disease (ILD) is the most frequent cause of drug-related mortality from EGFR tyrosine kinase inhibitors (TKIs). Yet, for patients with symptomatic osimertinib-induced ILD, the risk of recurrent ILD associated with EGFR TKI
Molly S.C. Li, M.B.B.S., Kirsty W.C. Lee, MBChB, Kevin K.S. Mok, MBChB, Herbert H.F. Loong, M.B.B.S., K.C. Lam, MBChB, Florence S.T. Mok, M.B.B.S., Landon L. Chan, MBChB, Y.M. Lau, M.B.B.S., K.P. Chan, MBChB, Joyce T.Y. Ng, MBChB, Wesley K.Y. Wong, M.B.B.S., Benjamin H.W. Lam, M.B.B.S., Allen C.C. Chen, BM, Matthew M.P. Lee, MBChB, Olivia H. Chen, MD, PhD, Tony S.K. Mok, MD   +15 more
doaj   +1 more source

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation

Thoracic Cancer, 2021
Background There are few studies that directly compare the effects of osimertinib on patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase ...
Yosuke Miyashita, Ryo Ko, Naoko Shimada, Yoichiro Mitsuishi, Keita Miura, Naohisa Matsumoto, Tetsuhiko Asao, Takehito Shukuya, Rina Shibayama, Ryo Koyama, Kazuhisa Takahashi   +10 more
doaj   +1 more source

Identification of Predictive Signatures for Osimertinib‐Associated Interstitial Lung Disease: Integrating Ensemble Machine Learning and Temporal Dynamics

Medicine Bulletin, EarlyView.
ABSTRACT The shift toward chronic management of EGFR‐mutant lung cancer underscores the urgent need to identify molecular features potentially relevant to osimertinib‐associated interstitial lung disease (ILD). This study aimed to investigate candidate molecular mechanisms of this toxicity by integrating putative osimertinib target profiles with ILD ...
Yilin Ye, Lianxin Zhu, Yunxiang Xie, Peng Sun, Cui Chen, Zhihua Zhu   +5 more
wiley   +1 more source

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis

A 60-year-old woman was diagnosed with cT4N3M1c stage IVB lung adenocarcinoma with epidermal growth factor receptor mutation of exon19 deletion. After one month of treatment with osimertinib, a cough and diffuse ground glass opacities were observed in ...
Masaki Ikeda, Rie Mori, Kazuo Tsuchiya, Taisuke Ito, Takuro Akashi, Yoshiyuki Oyama   +5 more
core   +1 more source

RETaliation - tackling rare resistance alterations to osimertinib

, 2023
RET fusions occur as a rare mechanism of acquired resistance to osimertinib in epidermal growth factor receptor mutation (EGFRm) positive non-small cell lung cancer (NSCLC) patients.
Sanjay Popat, Matthew G. Krebs, Krebs, Matthew G., Popat, Sanjay   +3 more
core   +1 more source

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

The Journal of Pathology, EarlyView.
Abstract Mucosal melanomas (MMs) are rare, aggressive cancers with poor outcomes and limited response to standard therapies. A significant knowledge gap exists regarding their genomic landscape and corresponding druggable targets. This study explores this issue through a multi‐omic analysis, including whole exome‐, RNA‐, and targeted sequencing, of ...
Matilde Monti, Martina Brigida Romanello, Luca Agnelli, Matteo Orlandi, Luca Bertoli, Sara Picinoli, Irene Pezzali, Giulio Eugenio Mandelli, Daniela Medicina, Giovanni Ribaudo, Adele Busico, Elena Conca, Vilma Pellegrini, Piera Balzarini, Daniele Gallucci, Anna Di Matteo, Davide Lombardi, Claudia Ghigna, Giancarlo Pruneri, Alessandra Gianoncelli, Marzia Rossato, William Vermi   +21 more
wiley   +1 more source